Received Nov 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | UNK | — | — |
| FLU3 | INFLUENZA (SEASONAL) (FLUBLOK) | SANOFI PASTEUR | UNK | — | — |
Patient received dose of flublok 23-Oct-2025 and after 2.5 weeks other dose on 09-Nov-2025, instead of Covid-19 vaccine, with no adverse event.; Patient received dose of flublok 23-Oct-2025 and after 2.5 weeks other dose on 09-Nov-2025, instead of Covid-19 vaccine, with no adverse event.; Initial information received on 10-Nov-2025 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 59 years old female patient who received dose of INFLUENZA TRIVALENT RECOMBINANT VACCINE [FLUBLOK] 23-oct-2025 and after 2.5 weeks other dose on 09-Nov-2025, instead of COVID-19 VACCINE, with no adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 23-Oct-2025, the patient received influenza trivalent recombinant vaccine, Solution for injection (dose, strength, lot, expiry, route and administration site: unknown) for immunization and on 09-Nov-2025 the patient again received 0.5 ml same vaccine via intramuscular route in left arm instead of covid-19 vaccine (route, dose,formulation, strength, expiry date and lot not reported), with no adverse event (extra dose administered) (wrong product administered) (latency same day). Information on batch number and expiry date corresponding to the one at time of event occurrence was requested. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.